Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: PMN; ARFXF

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease
News Update

Source:

The Canadian company continues seeking partners to leverage its discovery and development platform.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it identified several monoclonal antibody drug candidates for Parkinson's disease. The candidates precisely target only the toxic forms of the protein alpha-synuclein, considered to be a root cause of Parkinson's disease.

"We used our proprietary discovery platform to generate several antibody drug candidates for Parkinson's disease that precisely target only the toxic forms of alpha-synuclein," stated Dr. James Kupiec, ProMIS' chief medical officer. "Selectivity represents the essential feature of a successful antibody therapy, for it is critical that treatment not hinder normal forms of alpha-synuclein that play an important functional role in the brain. In preclinical studies, ProMIS antibody candidates showed a high degree of selectivity for only the toxic forms of alpha-synuclein in a side-by-side comparison with other alpha-synuclein targeting antibodies that are currently in development."

Preclinical in vitro studies demonstrated these candidates block neurotoxicity and the spreading of toxic alpha-synuclein while binding only to the toxic forms of the protein, the company noted.

ProMIS stated it has "created a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target these specific toxic forms."

"Competitive differentiation of ProMIS antibodies is key to ongoing partnering discussions with large pharmaceutical companies," the company stated.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.




Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe